blinatumomab
amgen,astellas
['leukemia', 'blinatumomab', 'emergent ']
congress | #ash22 | poster
pilar mart nez s nchez presented a poster with data from an ongoing trial investigating sc blinatumomab at 4 doses in pts with r/r b-all. across all cohorts, 66.7% of pts achieved cr/crh within 1 cycle. no dose limiting toxicities were observed.
#allsm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm